Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPSMA-7.3 (18F) PET in prostate cancer recurrence
NCT04186845Phase 3Completed
- Sponsor
- Blue Earth Diagnostics
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of flotufolastat f 18, sponsored by Blue Earth Diagnostics. Primary endpoints: Patient-level Correct Detection Rate at 90 days and Region-level Positive Predictive Value at 90 days. Started May 2020; status: completed.
02
Drugs
flotufolastat f 18
Beyond the preview
Go deeper on NCT04186845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186845.